132 related articles for article (PubMed ID: 22072214)
1. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.
Borghys H; Tuefferd M; Van Broeck B; Clessens E; Dillen L; Cools W; Vinken P; Straetemans R; De Ridder F; Gijsen H; Mercken M
J Alzheimers Dis; 2012; 28(4):809-22. PubMed ID: 22072214
[TBL] [Abstract][Full Text] [Related]
2. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
3. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
4. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
5. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.
Portelius E; Van Broeck B; Andreasson U; Gustavsson MK; Mercken M; Zetterberg H; Borghys H; Blennow K
J Alzheimers Dis; 2010; 21(3):1005-12. PubMed ID: 20634579
[TBL] [Abstract][Full Text] [Related]
6. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
[TBL] [Abstract][Full Text] [Related]
7. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
Borgegard T; Juréus A; Olsson F; Rosqvist S; Sabirsh A; Rotticci D; Paulsen K; Klintenberg R; Yan H; Waldman M; Stromberg K; Nord J; Johansson J; Regner A; Parpal S; Malinowsky D; Radesater AC; Li T; Singh R; Eriksson H; Lundkvist J
J Biol Chem; 2012 Apr; 287(15):11810-9. PubMed ID: 22334705
[TBL] [Abstract][Full Text] [Related]
8. Presenilin-1 but not amyloid precursor protein mutations present in mouse models of Alzheimer's disease attenuate the response of cultured cells to γ-secretase modulators regardless of their potency and structure.
Hahn S; Brüning T; Ness J; Czirr E; Baches S; Gijsen H; Korth C; Pietrzik CU; Bulic B; Weggen S
J Neurochem; 2011 Feb; 116(3):385-95. PubMed ID: 21091478
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
10. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
11. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
[TBL] [Abstract][Full Text] [Related]
12. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
13. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
[TBL] [Abstract][Full Text] [Related]
14. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.
Lanz TA; Karmilowicz MJ; Wood KM; Pozdnyakov N; Du P; Piotrowski MA; Brown TM; Nolan CE; Richter KE; Finley JE; Fei Q; Ebbinghaus CF; Chen YL; Spracklin DK; Tate B; Geoghegan KF; Lau LF; Auperin DD; Schachter JB
J Pharmacol Exp Ther; 2006 Nov; 319(2):924-33. PubMed ID: 16920992
[TBL] [Abstract][Full Text] [Related]
15. APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment.
Sjödin S; Andersson KK; Mercken M; Zetterberg H; Borghys H; Blennow K; Portelius E
Alzheimers Res Ther; 2015 Dec; 7(1):77. PubMed ID: 26689589
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.
Borghys H; Jacobs T; Van Broeck B; Dillen L; Dhuyvetter D; Gijsen H; Mercken M
J Alzheimers Dis; 2014; 38(1):39-48. PubMed ID: 23948925
[TBL] [Abstract][Full Text] [Related]
18. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
19. Potent γ-secretase inhibitors/modulators interact with amyloid-β fibrils but do not inhibit fibrillation: a high-resolution NMR study.
Yesuvadian R; Krishnamoorthy J; Ramamoorthy A; Bhunia A
Biochem Biophys Res Commun; 2014 May; 447(4):590-5. PubMed ID: 24747079
[TBL] [Abstract][Full Text] [Related]
20. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]